NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma The purpose of this...
Dec 14, 2006
79
FDA Approved for RRMM: Lenalidomide (Revlimid)
SUMMIT, N.J., June 29, 2006 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA)...
Dec 9, 2006
46
NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma
IFM 99-06 NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma In multiple myeloma, combination...
Dec 8, 2006
111
NCT00405756: Phase 3 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects
MM-015 study NCT00405756 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. The purpose...
Dec 7, 2006
100